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Background: Renal cell tumors (RCT) are clinically, morphologically and genetically 
heterogeneous. Accurate identification of renal cell carcinomas (RCC) and its 
discrimination from normal tissue and benign tumors is mandatory. We, thus, aimed to 
define a panel of microRNAs that might aid in the diagnostic workup of RCTs. 
 
Material and methods: Fresh-frozen tissues from 120 RCTs (clear cell RCC, papillary 
RCC, chromophobe RCC and oncocytomas: 30 cases each), 10 normal renal tissues and 
60 cases of ex vivo fine-needle aspiration biopsies from RCTs (15 of each subtype – 
validation set) were collected. Expression levels of miR-21, miR-141, miR-155, miR-183 
and miR-200b were assessed by quantitative reverse transcription-PCR (qRT-PCR). 
Receiver Operator Characteristics (ROC) curves were constructed and the areas under 
the curve (AUC) were calculated to assess diagnostic performance. Disease-specific 
survival curves and a Cox regression model comprising all significant variables were 
computed. 
 
Results: RCTs displayed significantly lower expression levels of miR-21, miR-141, and 
miR-200b compared to normal tissues and expression levels of all miRs differed 
significantly between malignant and benign RCTs. Expression analysis of miR-141/miR-
200b accurately distinguished RCTs from normal renal tissues, oncocytoma from RCC 
and chromophobe RCC from oncocytoma. The diagnostic performance was confirmed in 
the validation set. Interestingly, miR-21, miR-141 and miR-155 expression levels showed 
prognostic significance, in univariate analysis. 
 
Conclusions: The miR-141/miR200b panel accurately distinguishes RCC from normal 
kidney and oncocytoma in tissue samples, discriminating from normal kidney and 
oncocytoma, whereas miR-21, miR-141 and miR-155 convey prognostic information. This 
approach is feasible in fine-needle aspiration biopsies and might provide an ancillary tool 
for routine diagnosis. 
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Introdução: Os tumores de células renais (TCR) são clinicamente, morfologicamente e 
geneticamente heterogéneos. A correcta identificação dos carcinomas de células renais 
(CCR), bem como a sua discriminação do tecido normal e dos tumores benignos é de 
extraordinária relevância. Assim, o nosso objectivo foi definir um painel de microRNAs 
que pudessem auxiliar no diagnóstico de TCRs. 
Material e métodos: Cento e vinte tecidos congelados a fresco de casos clínicos 
randomizados (CCR do tipo células claras, CCR do tipo papilar, CCR do tipo cromófobo e 
oncocitomas: 30 casos cada), 10 tecidos renais normais foram seleccionados  para 
análise mlecular. Adicionalmente, como série de validação foram analisados 60 casos de 
biópsias aspirativas por agulha fina ex vivo (15 de cada subtipo ).. Os níveis de 
expressão do miR-21, miR-141, miR-155, miR-183 e miR-200b foram avaliados por PCR 
quantitativo em tempo real (qRT-PCR), após a síntese do cDNA. As curvas ROC ( 
Receiver Operator Characteristics) foram construídas e as áreas sob a curva (AUC) 
foram calculadas para avaliar o desempenho diagnóstico destes miRs. As curvas de 
sobrevida específica de doença foram calculadas para cada marcador molecular, tendo 
sido igualmente usado o modelo de regressão de Cox. 
Resultados: Os TCRs apresentaram níveis de expressão significativamente mais baixos 
nos miR-21, miR-141 e miR-200b, em comparação com tecidos normais e os níveis de 
expressão de todos os miRs diferiram significativamente entre TCRs malignos e 
benignos. A análise da expressão de miR-141/miR-200b distinguiu com elevadade 
acuidade os TCRs dos tecidos renais normais e dos oncocitomas, bem como os CCR do 
tipo cromófobo dos  oncocitomas. O desempenho da acuidade diagnóstica deste painel 
foi confirmado no grupo de amostras de validação. Na análise univariada,. os níveis de 
expressão dos miR-21, miR-141 e miR-155 demonstraram ter  valor de prognóstico.  
Conclusões: O painel miR-141/miR200b foi capaz de correctamente distinguir CCR de 
tecido renal normal e de oncocitoma, discriminando igualmente rim normal de 
oncocitomas. No entanto os miR-21, miR-141 e miR-155 demonstraram ser informativos 
quanto ao prognóstico. Esta abordagem é viável em biópsias aspirativas por agulha fina e 
pode constituir um método auxiliar para o diagnóstico de rotina hospitalar.
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1. Kidney cancer  
1.1. Epidemiology  
Currently, cancer remains the second leading cause of death in both genders in all 
ages in developed countries. Globally, kidney cancer accounts for approximately 4% of all 
cancers. In 2008, 273,500 new cases of kidney cancer were diagnosed and 116,300 
persons die from this disease worldwide [1].  
Currently, in the United States of America (USA), Kidney cancer is the 6th most 
frequent neoplasm in men and the 8th most frequent in women (Figure 1). Moreover, it is 
estimate for both sexes that 65,150 new cases of kidney cancer will be diagnosed as well 
as 13,680 deaths will occur de to this neoplasm [2].  
 
 
 
 
 
 
 
 
 
 In Europe, kidney cancer is 7th most common cancer in both sexes and the 
estimated number of kidney cancer cases and deaths in 2008 was 101,937and 45,096 
respectively, (Figure 2) for both sexes. In Portugal, the estimated number of new Kidney 
cancer cases in 2008 was 443 for males and 248 for females. In the same period, 347 
males and females died due to kidney cancer [3].  
The incidence of kidney cancer is quite variable across the countries. In 2008, the 
highest incidence rates were registered in Europe, North America and Australia, whereas 
the lowest incidence occurs in Asia, South American and Africa (Figure 2) [3]. This 
incidence rate variation may be attributable to differences in the access to health care, 
diagnostic imaging, genetic background, and prevalence of lifestyle or environmental risk 
factors [4]. 
Figure 1: Ten Leading Cancer Types for the Estimated New Cancer 
Cases by Sex, United States, 2013. Adapted from [2].  
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Figure 2: Incidence of different types of cancer in Europe for 2008. Kidney cancer 
(represented in dark blue) is the 7th most common diagnosed cancer in Europe. Adapted 
from [3]. 
 
Renal cell tumors (RCT) represent 90-95% of neoplasms arising from kidney [5]. It is the 
third most common cancer of the genitourinary tract and the most lethal urological cancer, 
since more than 40% of patients with renal cell carcinoma (RCC) die of the disease, 
opposite to the 20% observed for prostate or bladder cancers [6,7].  
Incidence rates for RCTs have been steadily increasing in Europe and in the USA 
for the last 3 decades. Compared to 1971, there has been a 5-fold increase in the 
incidence and a two-folds increase in mortality from RCTs. Although, the increased usage 
of imaging has resulted in more RCTs found by incidental detection, it does not entirely 
explain this augment in incidence [5,6]. 
 
Figure 3: Estimated age-standardized Kidney cancer incidence rate per 100,000, across 
the world. Adapted from [3]. 
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1.2. Risk Factors 
Most of the cases (96%) of RCTs are sporadic and only 4% are hereditary [8].  
There are multiple factors related to the development of RCTs. Some of them have been 
demonstrated in experimental models and in vitro studies, however only a few have been 
clearly established as etiologic factors [7]. Indeed, only smoking, obesity and hypertension 
are well-established factors associated with RCT[9]. Additionally. there are environmental 
risk factors such as occupational exposure to different chemicals, radiation and renal 
dialysis, that have been linked to RCT, nonetheless without a solid 
scientific/epidemiological support[10]. 
 
1.2.1. Sporadic kidney tumor 
Age and sex  
RCT is more frequent in males than in females, with a ratio of 3:2[7].  
The older individuals possess the higher risk compared to young individuals. In fact, the 
peak incidence occurs in the sixth decade of life, with the majority (80%) of the cases 
occurring within the 40 to 69-year-old population. Although Wilms tumor is the most 
frequent renal tumor in the childhood, RCTs represents between 2% to 6% of the total 
renal tumors in infants, without differences between sexes [7]. 
Smoking 
According with the International Agency for Research on Cancer (IARC), cigarette 
smoking is the most consistently established causal risk factor for RCC. Compared to 
never smokers, the risk augments about 50% in male and 20% in female smokers. A clear 
dose-response pattern of risk was observed with increasing amount of cigarettes smoked. 
Smoking cessation reduces the risk, although only among long-term quitters of ten or 
more years [11]. 
Obesity  
Excess body weight has been established as a risk for RCC in several case-
control and cohort studies, being estimated to account for over 40% of RCC, in the United 
States and over 30% in Europe. In prospective studies conducted worldwide, overweight 
and obese individuals at baseline were found to have elevated subsequent risks of renal 
cell cancer in a dose-response manner. In fact, each 5 kg/m2 body mass index (BMI) 
increase is estimated to enhance the risk in 24% and 34% for males and females, 
 6 
 
respectively [12]. Nevertheless, the mechanisms by which obesity may increase RCC risk 
are not well understood [10]. 
Hypertension and use of anti-hypertensive medications 
Hypertension or its treatment has been associated with the risk of RCC in several 
large prospective cohort studies [4]. Two studies measured blood pressure and observed 
an increased risk for RCC with elevated blood pressure in a clear dose-response 
association [13,14]. Users of diuretics and other anti-hypertensive medications were also 
indicated to elevate risk of renal cell cancer, but an independent effect from that of 
hypertension per se has not been established [11].  
The biologic mechanisms underlying the association between hypertension and 
renal cell cancer are elusive, but are hypothesized to include chronic renal hypoxia and 
lipid peroxidation with formation of reactive oxygen species [11].  
Acquired renal cystic disease 
Patients on long-term hemodialysis and patients with end-stage renal disease 
(ESRD) have higher predisposition to develop Acquired renal cystic disease (ARCD). The 
incidence of RCC in ARCD patients is reported to be 3 to 6 times higher than in the 
general population. It was also reported that a larger period of dialysis may be associated 
with a higher incidence of RCC. Moreover, the incidence ratio, for both genders, is higher 
in patients with ESRD than in general population, and the age at RCC diagnosis is 
younger in ESRD patients than in the general population [4].  
Occupation  
RCC is not generally considered an occupationally associated tumor, but an 
excess risk for renal cell cancer has been associated in variety of occupations.  
Trichloroethylene (TCE), considered a Group 2A “probable” human carcinogen by IARC, 
is certainly the most extensively chemically examined in relation to renal cell cancer risk. 
Epidemiologic evidence linking TCE to renal cell cancer is accumulating, with recent 
studies indicating a rising risk with increasing levels of exposure [11].  
Surprisingly recent study suggests a possible association of renal cell cancer with 
TCE employment in agriculture, particularly among women [15]. Other agents such 
asbestos, polycyclic aromatic hydrocarbons, gasoline and other petroleum products have 
also been associated to increased RCC risk, but these associations are not fully proven 
[10]. 
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1.2.2. Genetic factors 
Von Hippel-lindau (VHL) syndrome 
This syndrome is caused by germline mutations of VHL tumor suppressor gene, 
located on chromosome 3p25-26. Heritable clear cell RCC is caused by a germline 
mutation of one allele and an acquired mutation of the second allele[16]. These germline 
mutations are identified in nearly 100% of VHL-families. The VHL protein has an important 
role in cell cycle regulation and angiogenesis [17].  
Clinical manifestations include, among others, the risk for developing RCC, 
pheochromocytoma, pancreatic cysts and retinal angiomas. The RCC is a carcinoma of 
the clear cell type and may be solid or cystic occurring at an average age of 37 years 
[18,19]. Inactivation of VHL is specific to clear cell RCC and is not found in other 
histological cell types of RCC[19]. Penetrance for each of these manifestations is 
incomplete, for example, RCC is only found in 40-50% of VHL mutation carriers [4].  
Hereditary papillary renal cell carcinoma  
Hereditary papillary RCC is an autosomal dominant trait [7], caused by activation 
of the C-MET proto-oncogene which maps the chromosome 7q31.1 and encodes a 
growth factor receptor. Mutations lead to constitutive activation of the receptor, which 
promotes tumor growth. Type 1 papillary RCC is exclusively observed in this syndrome, 
which specifically does not exhibit symptoms in other organs [4]. 
Hereditary leiomyomatosis renal cell carcinoma 
Fumarate hydratase (FH) was identified as the gene responsible for hereditary 
leiomyomatosis renal cell carcinoma (HLRCC). Germinative mutations of FH gene have 
been detected in over 90% of North American individuals with hereditary leiomyomatosis 
renal cell carcinoma. The kidney tumors are mostly solitary and unilateral, although often 
display a mix of histologic patterns: papillary, tubulopapillary or solid [20].  
Birt-Hogg-Dube Syndrome 
The Birt-Hogg-Dub (BHD) gene maps to chromosome 17p11.2 and encodes the protein 
folliculin. This gene is also involved in sporadic RCC [7]. BHD is a syndrome in which 
patients develop cutaneous fibrofolliculomas, lung cysts, spontaneous pneumothoraced, 
and a variety of renal tumors, including chromophobe RCC, oncocytoma, and hybrid 
tumors that exhibit features of both of these entities[21]. However, other forms of RCC, 
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including clear cell RCC, have also been observed in this syndrome. Overall, penetrance 
for renal tumors is about 20% to 40%. Most renal tumors in BHD have limited biologic 
aggressiveness, although metastatic behavior and lethality have been already reported 
[4]. 
1.3. Pathology and classification  
1.3.1 Histological subtypes 
  Current RCTs’ histological classification was proposed in 2004 by the World Health 
Organization (WHO) [22]. This classification includes the achievements and contributions 
the prior classifications, in particular the Mainz (1986) and Heidelberg (1997) 
classifications [23,24] and describes categories and entities based on pathological and 
genetic analyses [25].  
RCTs include a heterogeneous group of tumors with a spectrum from benign to 
malignant lesions. Malignant tumors are sub-classified into clear cell renal cell carcinoma 
(ccRCC), also called conventional carcinoma, papillary renal cell carcinoma (pRCC) and 
chromophobe renal cell carcinoma (chRCC). Benign tumors are subclassified into 
metanephric adenoma and adenofibroma, papillary renal cell adenoma, and renal 
oncocytoma [23]. 
  RCTs are thought to arise from a multiplicity of specialized cells located along the 
length of the nephron. Both ccRCC and pRCC are thought to arise from the epithelium of 
the proximal tubule, whereas ChRCC, oncocytoma, and collecting duct RCC are 
considered to arise from the distal nephron, probably from the epithelium of the collecting 
tubule (figure 3). Each subtype has differences in genetics, biology and behavior [5].  
 
Clear cell renal cell carcinoma 
Clear cell renal cell carcinoma is the most frequent subtype of RCTs. It comprises more 
than 70% of all renal cell neoplasms [23].This is a malignant neoplasm composed of cells 
with clear or eosinophilic cytoplasm rich in glycogen and lipids [26]. Most of these tumors 
are solitary and occur with equal frequency in either kidney. Calcification, ossification and 
necrosis changes may occur. These tumors have a very vascular tumor stroma, regularly 
causing hemorrhagic areas. Some of them have a cystic appearance. This could be due 
to the necrosis (pseudo-cysts). Sometimes, ccRCC exhibit a pseudo-papillary architecture 
and often in these cases is difficult to distinguish them from pRCC [25]. 
Loss of chromosome 3p is a typical alteration in the vast majority of sporadic 
ccRCC[23]. These findings suggest the presence of one or more important tumor 
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suppressor genes (TSG) for RCC development on this chromosomal arm. The VHL tumor 
suppressor gene is one of the genes located at 3p and biallelic VHL inactivation is found 
in a high proportion of RCCs [27].  
 
 
 
 
 
 
 
 
Papillary renal cell carcinoma 
Papillary renal cell carcinoma is the second most prevalent subtype of RCTs, comprising 
approximately 10-15% of these tumors [28,29]. Papillary RCC has a variable proportion of 
papillae and could be multifocal or bilateral, normally containing necrosis, hemorrhage 
and cystic degeneration [25]. Histologically, it is characterized by epithelial cells forming 
tubules and papillae. The tumor papillae contain a fibrovascular core with aggregates of 
macrophages. Normally, psammoma bodies are also identifiable in this tumors [30]. 
Depending on the tumor cells morphology, pRCC is subclassified into two subtypes: Type 
1 tumors with papillae covered by small cells with scarce cytoplasm and Type 2 tumor 
cells, regularly of higher nuclear grade with eosinophilic cytoplasm[16]. Trisomies or 
tetrasomies of chromosomes 7 and 17 and loss of the Y chromosome are the most 
commonly observed genetic changes in these tumors, often together with various 
combinations of additional trisomies in chromosomes 12, 16, and 20 [31]. 
 
Figure 4: Classification of RCTs subtypes: The different RCTs subtypes are thought to 
originate from different parts of the renal tubular system: ccRCC/pRCC are supposed to 
arise of the proximal convoluted tubule and the chRCC/oncocytoma are supposed to arise 
of the collecting. Adapted from [27]. 
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Chromophobe renal cell carcinoma 
Chromophobe renal cell carcinoma is the third most common RCT subtype. It 
represents approximately 5% of the total cases of RCC [25]. Macroscopically, chRCC is 
well-circumscribed solid neoplasm, and highly lobulated. The tumor size is larger than 
other subtypes [32]. Microscopically, they usually have a solid growth pattern, at times 
tubulocystic, with broad fibrotic septa [33]. Two types of tumor cells can be present. The 
first type is characterized by large and polygonal pale cells, with abundant transparent 
cytoplasm and prominent cell membranes. Usually, they are admixed with a second 
population of smaller cells with a eosinophilic and granular cytoplasm[33]. 
This tumor type is genetically characterized by losses of numerous chromosomes, 
mainly chromosomes 1, 2,10,13,17 and 21 have described in approximately 80%, 
93%,93%,87%,90% and 70% of chRCC, respectively [33,34]. 
Oncocytoma 
Oncocytoma is the most prevalent benign RCT (approximately 5%) [30]. It is non-
capsulated, but well circumscribed. Histopathologically, this tumor has solid compact 
nests, acin tubules or microcystics. It is characterized by uniform round or polygonal cells. 
It has a densely granular eosinophilic cytoplasm. Necrosis and mitotic activity are rather 
uncommon in this tumor type [25,35].  
Genetically,  some cases show the translocation t(5;11)(q35,q13), whereas others display 
chromosome 1, 14 or Y loss [35].   
Figure 5: Morphologic characteristics among the RCTs subtypes. A- ccRCC; B- 
pRCC; C- chRCC and D: Oncocytoma.  
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1.3.2. Clinical and pathological staging 
One of the most frequently used staging systems is the American Joint Committee 
on Cancer (AJCC) and International Union Against Cancer (IUAC) tumor-node-
metastases (TNM) staging system. Herein, T represents the extension of the primary 
tumor, N refers to the lymph nodes status and M to distant metastasis. These criteria 
originate RCC grouping into four different categories [36,37]. Table 1 shows detailed 
information on TNM for Kidney cancer.  
Table 1: Staging and stage grouping for RCC. Adapted from [37].  
T-Primary tumor 
TX Primary tumor cannot be assessed. 
T0 No evidence of primary tumor. 
T1 
T1a 
T1b 
Tumor 7 cm or less in greatest dimension, limited to the kidney. 
Tumor 4 cm or less in greatest dimension, limited to the kidney. 
Tumor more than 4 cm but not more than 7cm in greatest dimension, limited to the 
Kidney. 
T2 
T2a 
 
T2b 
Tumor more than 7 cm in greatest dimension, limited to the kidney. 
Tumor more than 7 cm but less than or equal to 10 cm in greatest dimension, limited 
to the kidney. 
Tumor more than 10 cm, limited to the kidney. 
T3 
 
T3a 
 
T3b 
T3c 
Tumor extends into major veins or perinephric tissues but not into the ipsilateral 
adrenal gland. 
and not beyond Gerota’s fascia. 
Tumor grossly extends into the renal vein or its segmental (muscle containing) 
branches, or tumor. 
Invades perirenal and/or renal sinus fat but not beyond Gerota’s fascia. 
Tumor grossly extends into vena cava below the diaphragm. 
Tumor grossly extends into vena cava above the diaphragm or invades the wall of the 
vena cava. 
T4 T4 Tumor invades beyond Gerota’s fascia (including contiguous extension into the 
ipsilateral adrenal gland) 
 N – Regional Lymph Nodes 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Regional lymph node metastasis 
 M – Distant metastasis 
M0 No distant metastasis 
M1 Distant metastasis 
 Stage grouping 
Stage I T1 N0 M0 
Stage II T2 N0 M0 
Stage III T1 or T2 N1 M0 / T3 N0 or N1 M0 
Stage IV T4 Any N M0 / Any T Any N M1 
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1.3.3. Grading 
Grading refers to how closely the cancer cells resemble normal kidney cells under 
the microscope. The Fuhrman system, described in 1982 by Fuhrman et al, is the most 
commonly used grading system in RCC [38]. This grading system is based on the nuclear 
size, irregularity and nucleolar prominence. Fuhrman grading system has a scale of 1 
through 4 with grade 1 tumor being very little different from normal kidney cells and grade 
4 tumors are quite different from normal kidney cells [38]. Currently, this grading system is 
the most important prognostic predictor in RCC, principally in clear renal cell carcinoma 
(ccRCC) type [25].  
 
1.4. Therapy 
Current treatment for RCC patients can be divided into local therapy and systemic 
therapy.  
  1.4.1. Localized treatment  
Surgery is the only curative therapeutic approach for RCTs. For patients with T1 
tumors or indications such as solitary kidney, bilateral renal tumor localization, renal 
insufficiency, as well as, hypertension, diabetes or hereditary renal cell carcinoma 
syndromes, the therapy of choice is currently partial nephrectomy. Contrarily, this 
approach is not suitable for patients with locally advanced tumor growth or unfavorable 
location. In these situations, the curative therapy remains radical nephrectomy either by 
laparoscopic or open surgery [16,39]. Radical nephrectomy is the recommended standard 
of care for patients with T2 tumors and smaller masses not treatable by partial 
nephrectomy, regardless of histological subtype [16,39]. Lymph node dissection does not 
appear to improve long term survival following nephrectomy [40].  
Regarding surgical treatment of metastatic RCC, tumor nephrectomy is curative 
only if surgery can excise all tumor deposits. For most patients with metastastatic 
disease, tumor nephrectomy is palliative and complementary systemic treatments 
are necessary [39].  
Radiotherapy may be useful for selected symptomatic patients with non-resectable brain 
or osseous metastases which do not respond to systemic treatment approaches [39].  
1.4.2. Systemic therapy 
Hormonal and chemotherapy are not standard treatment in RCC due to low 
response rates [16]. 
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Systemic therapy has been rather ineffective to in metastatic renal cell carcinoma 
(mRCC). Chemotherapy as monotherapy is not recommended, at all. Opposite results 
have been accomplished with immunotherapy, namely interferon-α(IFN-α) has proven to 
increase survival over hormonal therapy [39]. Around 5% to 15% of cases of mRCC 
respond to IFN-α, however most of these responses are partial or short duration [16,41]. 
Interleukin-2(IL-2) has also been documented with response rates of approximately 7% to 
27% [41].  
Recent advances in molecular biology have led to the development of novel agents for 
treatment of mRCC, such as sunitinib, pazopanib, bevacizumab, temsirolimos, 
everolimus. These drugs have shown efficacy in phase III trials, and were recently 
approved by the Food and Drug Administration (FDA) for application in RCC patients 
[16,39]. After treatment with these targeting agents, a substantial improvement of 
progression-free and overall survival has been achieved [39].  
 
1.5. Tumor prognosis  
There has been a gradual improvement in RCC prognosis over the last decades, 
with 5-year relative survival rates as high as 64% in 2002, compared with less than 40% in 
the early 1960s [16].  
Factors influencing prognosis can be classified into anatomical, histological, 
clinical, and molecular. Anatomical factors are usually included in the TNM staging 
classification system [39]. According to this staging system, the 5 year cancer-specific 
survival rates ranged from 97% for pT1A to 20% for pT4. Presence of lymph node 
metastases predicts a poor prognosis, with cancer-specific survival rates of 5–30% and 0–
5% at 5 and 10 years, respectively. Metastases to other organs (lung, bone, brain) are 
associated with survival rates of 50%, 5-30% and 0-5% at 1,5 and 10 years, respectively 
[16].  
The histological variables mainly include the Tumor grade and RCC subtype. 
Concerning the tumor grade, grades 1/2 have slow growth and spread and tend to have a 
good prognosis, whereas the 3/4 have a worse prognosis. However, grading of tumor 
cells is an important factor in assessing prognosis, mostly in ccRCC [42]. In univariate 
analysis, there is a trend of better prognosis for patients with chRCC when compared with 
pRCC and ccRCC. However, in multivariate analysis, TNM stage, Fuhrman grade and the 
performance status, but not histological classification, are preserved as independent 
prognostic variables. Tumor necrosis is also a strong independent predictor of poor 
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outcome for ccRCC but not for chrRCC or pRCC. Microvascular invasion and presence of 
sarcomatoid features are also reported as adverse prognostic indicators [16].  
Clinical factors consist of patient performance status, localized symptoms, anemia 
and platelet count.  
Finally, and concerning the molecular markers investigatedto date, none of these 
markers has provided evidence to improve the predictive accuracy of existing prognostic 
systems [39]. 
The clinical behavior of RCC depends on complex interactions between several 
prognostic factors, nonetheless the most useful predictors of patient outcome, currently 
available, comprise patient performance status, tumor stage and grade [16].  
 
1.6. Symptoms and diagnosis 
Renal tumors are asymptomatic and non-palpable in early stages of disease. More than 
50% of renal tumors are detected incidentally by imaging examinations to investigate non-
specific symptoms or diseases [43]. The standard presentation of RCC includes the 
classic triad of hematuria, pain and a flank mass, but more than 40% of RCC patients do 
no exhibit these three symptoms. In fact, the only 10% of RCC patients whom present any 
symptom often have advanced disease at diagnosis [5,44].  
Because histological subtypes differ in clinical aggressiveness and prognosis 
[45,46], accurate classification is required for appropriate patient management. Moreover, 
most RCTs are clinically silent at their earliest stages, and 20-30% are diagnosed when 
metastatic spread has already occurred [47]. The widespread use of imaging techniques 
(mainly ultrasonography) has increased the detection of suspicious renal masses, 
prompting new pre-operative diagnostic challenges as histological diagnosis using needle 
biopsy material, however this appoach meets important limitations, hampering an 
accurate categorization in many instances [48]. Renal tumors biopsy is increasingly being 
used in diagnosis before ablative and systemic therapy. Biopsy aims to determine 
malignancy, subtype and grade of the renal mass. In most series, a core biopsy 
demonstrates high specificity and high sensitivity for the presence of malignancy, although 
10–20% of biopsies are inconclusive [39]. In this setting, diagnosis relies mainly on 
morphologic features, some of which are shared by tumor subtypes [49]. The 
discrimination between chRCC (mainly the eosinophilic variant) and oncocytoma is one of 
the most critical, in which differential diagnosis might be difficult. However, chRCC is a 
malignant neoplasm, capable of local invasion and metastatic spread, whereas 
oncocytoma is a benign tumor, therefore requiring two different management strategies.  
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 1.7. The problem distinguishing Oncocytoma 
from Chromophobe Renal Cell Carcinoma 
As mentioned above, the most important and challenging differential diagnosis in 
renal neoplasms are between oncocytoma and chRCC  particularly its eosinophilic variant 
with the abundant granular eosinophilic cytoplasm. This might be due to the fact that they 
have a common origin in nephron, specifically in the collecting duct [50]. Importantly, they 
should be correctly diagnosed because both tumors have different behaviors and clinical 
outcomes (oncocytoma is a benign tumor, whereas chRCC is a malignant tumor with 
metastatic potential). 
Over the years, several attempts have been made to assist morphology in the 
differential diagnosis between chRCC from oncocytoma, including immunohistochemical 
profiles [47,48,51], histochemical stains [52] and gene expression analysis [53]. However, 
sensitivity and specificity of those techniques are suboptimal and prompt the need for 
more accurate biomarkers, although,  the results of these studies are inconsistent [53].  
Concerning morphological features, the presence of fibrous capsule and its 
thickness has been described as a feature to distinguish chRCC and oncocytoma, 
however, a large number of cases are needed to support this finding [50].  
Immunohistochemical markers had also been tested to distinguish chRCC and 
oncocytoma, namely cytokeratin 7 , claudin 7 and parvalbumin, which were described as 
preferentially expressed in chRCC over oncocytoma [47,48], S100 protein and CD82, 
which were found to be preferentially expressed in oncocytoma [48,51]. More recently, 
Lee et al described caveolin-1 and MOC-31, which show a preferentially expression in 
chRCC and not in oncocytoma [53]. Nonetheless, the results of these studies are 
inconsistent and need to be further confirmed by additional studies [48,54,55].  
Similarly, some reports have suggested that Hale´s colloidal iron stain as a helpful 
method for the differential diagnosis of chRCC from oncocytoma. Nevertheless, this stain 
is technically challenging and the results are quite variable, and low reproducibility [50,52].  
Moreover, gene expression studies have been also performed in order to find a  
gene/ panel of genes amenable to distinguish this two subtypes of RCTs . Specifically, T-
cell differentiation protein 2 (MAL2), prominin 2 (PROM2), protease, serine, 8 (PRSS8), 
epithelial splicing regulatory protein 1 (FLJ20171) and adaptor-related protein complex 1, 
Mu 2 subunit (AP1M2) gene’s expression was evaluated. These genes showed a 
differential expression between chRCC and oncocytomas [54]. However, the clinical 
diagnostic usefulness of these markers lacks of validation. 
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Interestingly, some recent studies have attempted to discriminate RCTs subtypes 
using epigenetic alterations as will be later detailed.  
 
2. Epigenetics 
The term “Epigenetics” was first used by C. H. Waddington in 1939 [56]. It derives from 
the word “epigenesis”,  and it was first introduced to describe “the causal interactions 
between genes and their products, which bring the phenotype into being” [57], thus 
relating genes and development even though the Watson-Crick Deoxyribonucleic Acid 
(DNA) structure had not yet been reported. During almost half a century, the word 
epigenetics was used in this sense [57].  About  forty- three  years later, in 1996, Riggs 
and colleagues defined  epignetics as: “the study of mitotically and/or meiotically heritable 
changes in gene function that cannot be explained by changes in DNA sequence” [58]. As 
used nowadays the term “Epigenetics” comprehends both heritable and transient changes 
in gene expression that do not involve a change in primary DNA sequence [58,59].  
Epigenetic mechanisms that control gene expression can be divided into three main 
categories: DNA methylation, post-translational histone modifications, and expression of 
non-coding RNAs [60]. Together these different mechanisms generate the so called 
“epigenome” which is defined as: “Act to regulate what genetic information can be 
accessed by the transcription and translation machinery” [61]. When epigenetic patterns 
are deregulated it might induce abnormal activation or inhibition of different pathways 
which can lead to a disease , such as occurs in cancer [62].  
2.1.1. DNA Methylation  
DNA methylation is perhaps the most widely studied epigenetic mechanism [63]. 
This modification is found in genome of almost all organisms, and the patterns and levels 
are variable across species [64,65].  
DNA Methylation, involve the addition of methyl group to the fifth carbon position of 
a cytosine, originating in the formation of a new base- 5-methylcytosine (m5C). This 
reaction is catalyzed by DNA methyltransferases (DNMTs), using S-adenosyl-L-
methionine (SAM) as a donor of methyl groups [66,67]. So far, two different classes of 
DNMTs have been described: The maintenance and de novo methyltransferases. The 
most important maintenance is DNMT1, and its major function happens during DNA 
replication, and has preferential activity for hemi-methylated DNA. Whereas de novo 
methyltransferases include DNMT3A and DNMT3B, which preferentially methylate 
previous unmethylated Cytosine-Phosphate-Guanine (CpG) sequences, but are capable 
to methylate hemi-methylated DNA [65,68]. DNA methylation is associated with gene 
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silencing expression. Globally, there are two alternative mechanisms by which DNA 
methylation inhibits gene expression. This may occur through the obstruction of 
transcriptional activators on methylated regions within or near the promoter, and / or 
indirectly through by recruiting methyl-CpG-binding domain proteins (MBDPs) that induce 
chromatin changes. This family of proteins use transcriptional co-repressor molecules to 
silence transcription and to modify surrounding chromatin, providing a link between DNA 
methylation and chromatin remodeling [68,69]. 
In mammals, DNA methylation occur mostly in cytosines that precede guanines, 
these are called dinucleotide CpGs [56]. CpG dinucleotides, are not distributed across the 
human genome but are instead concentrated in short CpG-rich DNA stretches called 
“CpG islands”, in which CpG´s concentration is higher than elsewhere in the genome. 
CpG islands are preferentially located at the 5´end of genes [61,70]. In fact, they occupy 
about 60% of the human gene promoters [63].  
Generally, the CpG islands are not methylated in normal cells and a few percent 
(~6%) become methylated in tissue-specific manner during early development or 
differentiated tissues, which results in stable silencing of the associated promoter, for 
instance in genomic imprinting and X-chromosome inactivation [64,66]. Furthermore, 
alterations in DNA methylation ate linked to many human diseases, including cancer [69].  
2.1.2. Histone modifications 
Histones are the chief protein components of chromatin, which are composed with 
by an octamer of histones (two H2A-H2B dimers and one H3-H4 tetramer) to form a 
nucleosome, which are the fundamental unit of chromatin [71], and presents of a globular 
C-terminal domain and a flexible unstructured N- terminal tail [72]. The N-terminal tail of 
histones can undergo a variety of post-translational covalent modifications of specific 
residues, namely: methylation, acetylation, ubiquitylation, sumoylation and 
phosphorylation [73]. From these, methylation and acetylation are the most studied, and 
the best characterized. These modifications are known to play a critical role in chromatin 
packaging and key cellular processes, such as replication, transcription, and DNA repair 
[71]. Acetylation is catalyzed by histone acetyltransferases (HATs) and can be reversed 
by the enzymatic action of histone deacetylases (HDACs). In general, acetylation of lysine 
residues decreases the affinity of histones for DNA creating an “open” chromatin 
conformation that allows gene transcription [74].  
Histone methylation-modifying enzymes include histone methyltransferases (HMTs) and 
histone demethylases (HDMs), which present high substrate specificity [71]. Contrarily to 
acetylation, histone methylation can lead either to transcriptional activation or repression 
depending upon which residues are modified and the type of modifications present. For 
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example, methylation of lysines 4, 36, and 79 of histone 3 (H3K4me3, H3K36me, and 
H3K79me) is associated with transcriptionally active regions, whereas methylation of 
lysines 9 and 27 of histone 3 (H3K9 and H3K27) and of lysine 20 of histone 4 (H4K20) is 
commonly linked to heterochromatin formation and the presence of inactive promoters 
[75]. Genome-wide histone modifications have also been described in malignant cells. 
However, the current knowledge concerning the involvement of histone modifications in 
tumorigenesis is less clear than DNA methylation modifications. These two different 
epigenetics phenomena are thought to be inter-dependent [56,76].  
 
2.1.3. Non-coding RNAs 
Non-coding RNAs (ncRNAs) are RNAs that despite not encoding proteins are biologically 
functional [77,78]. Recently, ncRNas have been implicated in different molecular, cellular 
and organismal events in eukaryotic cells. It been established to play a role in 
transcription regulation through their interaction with several transcription factors, and also 
interacts with chromatin-modifying enzymes demonstrating its importance in maintaining a 
proper chromatin conformation [79,80]. Other variety of complex mechanisms such as 
gene silencing, DNA imprinting, and RNA interference  have already been connected to 
theirs function [81]. Therefore, changes in ncRNAs expression levels have been 
associated in development of many different human diseases, including a cancer [77,78]. 
NcRNAs comprise several different classes, according to their length and their function. 
MicroRNAs (miRNAs), transcribed ultraconserved regions (T-UCRs), small nuclear RNAs 
(snoRNAs), PIW-interacting RNA (piRNAs), large intergenic non-coding RNAs (lincRNAs), 
and the heterogeneous group of long non-coding RNAs (lncRNAs) [77,78]. Nevertheless, 
the functional relevance of the non-coding genome in normal development and physiology 
and for disease have been particularly evident for miRNAs [78].  
 
2.2. MicroRNAs Biogenesis and Mode of 
Action 
MiRNAs have been the most widely investigated class of ncRNAs. Constitutes a group 
of endogenous single-stranded non-coding small RNA of approximately 18-22 nucleotides 
in length [78,82]. The first miRNA to be identified was link-4, in 1993, by Victor Ambros 
and colleagues, from a study of developmental timing in the nematode C. elegans [83]. 
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Since then, hundreds of miRNAs have been identified and currently, more than 2000 
human miRNAs are registered in miRBase database.  
The biogenesis of miRNA begins in the nucleus, and the miRNAs are transcribed by 
an RNA polymerase II into a capped and polyadenylated precursor with hairpin structures, 
called pri-miRNA [84,85]. Following transcription, a pri-miRNA forms a stem-loop structure 
with a double-stranded RNA (dsRNA) of approximately 33 nucleotides (Figure 2-a) [86]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pri-miRNA are recognized and cleaved in the nucleus by a complex known as 
microprocessor which is composed of Rnase II Drosha and Di George syndrome critical 
region 8 (DGCR8). The cleavage produces a hairpin RNA of about 65 nucleotides that is 
called a precursor-miRNA (pre-miRNA) [86]. Surprisingly, Drosha mediated processing of 
pri-miRNA into pre-miRNA is not obligatory, alternatively some miRNAs (named mirtrons) 
which are located in short introns of host genes, bypass the Drosha processing step and 
the pre-miRNA are derived as a byproduct of splicing event. After splicing, the excised 
intron is debranched and trimmed by lariat-debranching enzyme to generate the pre-
miRNA [78,87]. At this moment, the mirtron pathway merges with the canonical miRNA 
pathway[88] and the harpin pre-miRNA is then exported from the nucleus to cytoplasm, by 
Figure 6: miRNA biogenesis and mechanism of action. Adapted from [90] 
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exportin-5(XPO5) in complex with Ran-GTP, and is further processed by another RNase 
enzyme called Dicer, which acts in complex with the dsRNA-binding protein Trans-
activator RNA-binding protein 2, (TARBP2) [87,89]. The cleavage results into an imperfect 
RNA (dsRNA), duplex-designated miRNA, witch named miRNA/miRNA*, with 
approximately for 19-24 nucleotides [90,91].Only one strand of the miRNA duplex(mature 
miRNA), preferentially in 5´ segment  more loosely paired with the opposite strand is 
selected to function as a mature mirRNA , and are incorporate into a large protein 
complex (Argonaute protein) to form the RNA-induced silencing complex (RISC), whereas 
the passenger strand is subjected to degradation [82,92]. RISC leads the regulation of 
gene expression at post-transcriptional level, binding mostly through partial 
complementarity to a sequence in the target mRNA generally located at the 3’-
untranslated region (3’UTR) [84,93]. 
Depending on level of complementarity between miRNA and its target mRNA 
sequence, this regulation is performed by two main ways: if perfect or near-perfect 
complementarity is established, the RISC induces mRNA degradation; if they exhibit an 
imperfect pairing, mRNA translation into a protein is blocked [87,94](Figure 2). Although 
the most frequent site of interaction is the 3´ UTR region of the target mRNA, recent 
studies have described that miRNAs could also bind to the open reading frame sequence 
(ORF) sequences, as well as the 5´UTR. This interaction has been associated with 
activation rather than repression [90,95]. Interestingly, a specific miRNA may regulate 
multiple mRNAs in the same manner that a single mRNA may be targeted by multiple 
miRNAs [92,93]. Additionally, miRNAs can also regulate gene transcription by binding 
directly or by modulating methylation patterns at target gene promoter. Furthermore, 
miRNA can also bind directly to proteins, in a seed sequence in a RISC-independent 
manner, interfering with their RNA-binding functions [90,96]. While still poorly 
documented, it has been described that miRNAs are able to regulate gene expression at 
transcriptional level by direct binding to the DNA [97,98]. In mammalian cells, it is 
estimated that miRNAs control the activity of  more than 60% of protein-coding genes and 
they play crucial roles in the regulation of multiple pathways and cellular processes, 
including proliferation, differentiation, apoptosis, development and metabolism [78,92,99]. 
Due to their involvement in mostly all biological mechanisms, the abnormal expression of 
miRNAs contributes to a range of human diseases, including cancer [78,88].  
MiRNA genes can be located within coding mRNAs (40% are intronic or exonic) or in 
the intergenic regions. About one-third of miRNAs are organized in clusters, and these 
may affect several miRNAs altering thousands of protein targets[100]. 
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2.3. MicroRNAs and cancer 
Cancer is a complex genetic disease caused by the accumulation of mutations, 
which lead to deregulation of gene expression and uncontrolled cell proliferation. Given 
the wide impact of miRNA on gene expression, it is not surprising that a large number of 
altered miRNAs have been connected in cancer [84].  
The first evidence linking aberrant miRNA expression and human cancer, was 
found in B-cells leukemia in 2002 by Calin e colleagues [101]. Actually, altered expression 
of miRNAs are considered a common characteristic of all human tumors, and they can 
initiate carcinogenesis or drive a tumor progression [100]. 
Altered expression of miRNAs in cancer have been associated to different 
mechanisms (Figure 7) [102]. Similarly to protein-coding genes, more than half miRNA 
genes are located in chromosomal regions that frequently exhibit amplification, deletion or 
translocation [103-105]. Mutations and single nucleotide polymorphisms (SNPs) within 
miRNAs have also been also described in different types of cancer [106,107].  
 
 
 
Epigenetics changes such as DNA methylation can also lead to microRNAs’ 
expression deregulation in cancer. An extensive analysis of genome sequenced for 
miRNA genes have shown that approximately half of them are associated with CpG 
islands, suggesting that they could be a target of this mechanisms’ regulation [87]. 
Conversely, methylation is not the only epigenetic mechanism that might affect miRNA 
expression, since it has been shown that histone deacetylase inhibition (HDAC) inhibitors 
have the potential to promote downregulation of some miRNAs [99]. Furthermore, miRNA 
deregulation can result from increased or decreased transcription activity of transcription 
factors at the promotor. In addition to genetic and epigenetic alterations, miRNA 
expression can also be modulated by defects in the machinery involved in miRNA 
Figure 7: Mechanisms of miRNA dysregulation. Adapted from [102]  
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biogenesis [87]. Indeed, changes in miRNA levels might be a consequence of genetic 
alterations in different molecules involved in miRNA processing, such as Drosha [88], 
XPO5[108], Dicer [109], and TARBP2 [110]. These alterations affect the production of the 
pri-miRNA, their processing to mature miRNA form and/or interaction with mRNA targets, 
and have been already implicated in neoplastic transformation [78].  
 
 
Figure 8: MicroRNAS as oncogenes or tumor suppressor genes. Adapted from [87]  
 
MiRNAs have been suggested to function as oncogene or tumor suppressor based 
on their inhibition of tumor-supressive or oncogenic target mRNAs [87,99] (Figure 8). 
MiRNA with oncogenic activities are named oncomirs. This term indicates the miRNA are 
constitutively overexpressed and promote tumor cell growth by inhibing tumor suppressor 
genes or genes that control cell cycle progression, differentiation or apoptosis. By 
contrast, tumor suppressor miRNAS, anti-oncomir usually prevent tumor development by 
inhibiting oncogenes [111].  
Furthermore, tumor suppressor miRNAs could undergo loss of function in tumors 
due to chromosomal rearrangements, deletions or mutations [92]. Although it is known 
that both overexpression and depletion of specific miRNAs play pathogenic roles in tumor 
progression, most human tumors are characterized by a general defect in miRNA 
production that results in global downregulation of miRNA expression [112]. Interestingly, 
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some miRNAs may have dual functions, and act both as tumor suppressors and 
oncogenes, depending on the context [93].   
2.4. MicroRNAs as tumor biomarker 
Recent studies have demonstrated that different tumors and tumor subtypes have specific 
miRNA signatures which may be useful as diagnostic and/or prognostic markers [86,91]. 
MiRNA signatures can distinguish not only between normal and tumor tissues and identify 
tissues origin, but also they can discriminate different subtypes of a particular cancer, or 
even specific oncogenic abnormalities [87]. An important issue in clinics is clearly 
represented by the need of biomarkers for an early diagnosis, which are particularly 
important considering that survival and prognosis of patients depends on the stage of the 
tumor at the time of detection, with an early diagnosis usually been associated with best 
prognosis. MiRNAs have shown a great promise as new early diagnosis biomarkers, for 
example in study published by Du Rieu and colleagues in 2010 [87,113]. Lu and colleges 
showed that miRNA expression profiles indicate that miRNAs are a better indicator for 
discriminate cancer tissues from normal tissues and can successfully classify even poorly 
differentiated tumors [112]. Furthermore, miRNAs can function as truthful molecular 
markers because they are relatively stable (more stable than mRNA) and resistant to 
RNase degradation, probably due to their small size. [87]. MiRNAs can be isolate from 
different types of biological material, such formalin-fixed paraffin-embedded (FFPE) 
specimens [114], from fresh frozen samples [115], and from different biological fluids, 
such as blood (total blood, plasma or serum) [43,116] and urine [117]. Additionally to the 
expression profile studies based on microarray platforms, other methods for analyzing 
microRNAs have been developed, as quantitative real-time polymerase chain reaction 
(RT-qPCR) [49] and in situ hybridization [118].  
2.5. MicroRNAs deregulated in kidney cancer.  
Deregulation of miRNA expression seems to be critical for RCC development and 
progression [119]. Indeed, several miRNA have been found to be deregulated in RCTs, 
although most of the studies have studied mainly on ccRCC. Some of them were found 
upregulated (miR-16 [120,121];miR-18a [122] ;miR-20a [122];miR-21 [76,121,122]; miR-
34a and miR-34-b [76,121]; miR-92a [122]; miR-155 [76,119-121], miR-185 [76,121]; miR-
210 [76,121,122]; miR-224 [76,120] and let-7 [121,122], whereas others were found 
downregulated ( miR-125b [76,121]; miR-141 [76]; miR-133b [76]; miR-200b [76]; miR-
200c [76]; miR-429 [76,121]; miR-506 [121,123]; miR-508-3p [121,123]; miR-509-5p [123]; 
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miR-509-3-5p [121,123]; miR-510 [76,121] and miR-541 [76,121,123]. These miRNAs are 
the most consistently reported alterations.  
Only a limited number of studies addressed the potential use of miRNAs as RCC 
detection biomarkers. In this regard, differential miRNA expression patterns in neoplastic 
and non-neoplastic renal tissues, as well as among different renal tumor subtypes have 
been documented. The discrimination between ccRCC and normal kidney tissue might be 
accomplished by a panel of nine miRs (miR- 21,miR-34a,miR-142-3p,miR-155,miR-
185,miR-200c,miR-210, miR-224, and miR-592) [115]; a combination of miR- 141 and 
miR-155 [120] or through the differential expression of miR-92a, miR-210, and miR-200c 
[119]. Moreover, regarding miRNAs signatures for each RCT subtypes, analysis of miRNA 
microarray data showed that tumors derived from the proximal nephron (ccRCC and 
pRCC type I) and tumors derived from the distal nephron (oncocytomas and chRCC) can 
be distinguished by their miRNA profile (Valera et al., 2011), supporting previous 
observations for ccRCC and chRCC by Nakada and colleagues [124]. These differential 
expression patterns of microRNAs might be also used to subclassify RCTs [49,125,126]. 
Indeed, Petillo and colleagues showed that ccRCC and pRCC were differentially 
expressed in 27 miRNAs, with ccRCC expressing higher levls of miR-203 and miR-424 
compared to pRCC, whereas pRCC expressed higher levels of miR-31 and mir-504 than 
ccRCC. Additionally, similar miRNA expression patterns was reported for chRCCs and 
oncocytomas.[126]. In a different study by Valera and colleagues miR-143, miR-19a, miR-
21, miR-29a, miR-181a, and miR-378 were found to be only expressed by chRCC, 
whereas mir-146a was preferentially expressed in oncocytoma [119]. Additionally, chRCC 
showed higher levels of miR-203, mir-200b, miR-197, and miR-320 than oncocytoma, 
whereas miR-186 was overexpressed in oncocytoma comparing with chRCC [49,126]. 
However, most of these studies only performed microarray analysis in a limited number of 
samples, and usually not representing all histological subtypes. Finally, two recent studies 
investigated miRNA expression levels in RCC patients’ serum and identified miR-1233 
and mi-210 as promising biomarker for RCC detection and monitoring [43,116].  
Altered levels of miRNAs might also provide prognostic information in ccRCC. 
Interestingly, it was previously showed that miR-155 and miR-21’s overexpression 
correlates  with tumor size [122]. Moreover, in a different study, higher levels of miR-210 
were found in tumors displaying the highest Fuhrman grade [119]. Furthermore, 
overexpression of miR-32 as well as of miR-210, miR-21, let-7i, and miR-18a correlated 
with poor survival [122,126,127]. Additionally lower miR-106b levels were associated with 
metastatic disease and poorer relapse-free survival [128].
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Aims of the study
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In two recent reviews [129,130], we found that five microRNAs (miR-21, miR-141, miR-
155, miR-183 and miR-200b) had been suggested to display diagnostic or prognostic 
value in RCT [49,115,120,124,126]. Thus, we aimed to confirm and extend those findings 
through expression analysis of a five miRNA panel in a single series of RCT, comprising 
the four major subtypes.  
Specifically, the main objectives of this thesis were:  
 Evaluate the expression of a panel miRNAs in fresh-frozen tissue to: 
o Distinguish tumor and normal tissue. 
o Distinguish different histological subtypes.  
o Determine its diagnostic value. 
o Determine its prognostic value. 
 
 Assess the two best performance miRNAs in ex vivo aspirate biopsy samples from 
kidney cancer patients. 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Material and methods
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1. Clinical samples  
A total of 130 fresh frozen tissues were prospectively collected and included in this 
study, including 120 renal cell tumors, comprising 30 cases of each of the four major 
subtypes (ccRCC, pRCC, chRCC, and Oncocytoma), and 10 normal tissues. Additionally, 
60 cases of ex vivo biopsies (15 of each subtype) were included for further validation. 
These samples were selected from patients diagnosed and treated at the Portuguese 
Oncology Institute – Porto (Portugal), between 2003 and 2007, who underwent partial or 
total nephrectomy, after informed consent. Normal tissues were obtained from 
morphologic normal kidney tissue of patients that were subjected to nephrectomy due to 
urothelial carcinoma. Ex vivo biopsies were obtained during surgery and tumor tissue 
samples were immediately snap-frozen, stored at -80ºC and subsequently cut in a 
cryostat for RNA extraction.   
Fuhrman grade and TNM stage of all cases of RCC were previously assessed by 
histological slides from formalin-fixed paraffin embedded tissues fragments from the same 
surgical specimens. Relevant clinical data was collected from clinical charts. This study, 
as well as the use of samples and the access to clinical data, was approved by the 
Institutional Review Board (Comissão de Ética) of Portuguese Oncology Institute – Porto, 
Portugal. 
 
2. RNA extraction   
Total RNA was extracted from fresh frozen tissues and ex vivo biopsies using 
Trizol® Reagent (Invitrogen, Carlsbad, CA, USA), according to manufacturer’s 
instructions. Briefly, 1500μL of Trizol® Reagent was added to each 2.0mL tube and 
tissues were homogenized using a rotor-shaker. Tubes were incubated for 5 to 10 min at 
room temperature and then 300μL of Chloroform (Merck, Germany) were added. In 
biopsies samples the protocol was similarly performed, but the quantitative Trizol® 
Reagent and chloroform were 500μL and 200μL, respectively. Tubes were vigorously 
hand-shacked for 15sec and incubated for 3min at room temperature, followed by a 15min 
12,000g centrifugation at 4ºC. Then, the upper phase was collected. RNA was purified 
using the PureLinkTM RNA Mini Kit (Invitrogen, Carlsbad, CA, USA), according to 
manufacturer's indications.  RNA concentration and purity ratios were then evaluated 
using NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, USA). Aditionally, 
RNA quality was checked by electrophoresis in a 2% agarose gel. 
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3. Reverse transcription 
Reverse transcription (RT) was performed using TaqMan MicroRNA Reverse 
Transcription Kit and Megaplex RT human pool A (Applied Biosystems, Foster City, CA, 
USA), from total RNA samples (Figure 9). The reaction mix had a final volume of 12μL 
and included 3μLof total RNA (750ng), 1.6μL of megaplex RT primers (10x), 0.4μL of 
dNTPs with dTTP (100 mM), 3μL of multiScrible reverse transcriptase (50 U/μL), 1.6μL of 
10x RT buffer, 0.2μL of RNase inhibitor (20 U/μL) and 0.4μL of nuclease-free water. 
Reactions were incubated in PCR tubes followed by 40 cycles at 16°C for 2min, 42°C for 
1min and 50°C for 1sec, before 85°C for 5min. 
 
 
 
 
 
 
 
 
4. Quantitative real time RT-PCR 
Quantitative reverse transcription-PCR (qRT-PCR) was performed using TaqMan® 
Small RNA Assays (Applied Biosystems, Foster City, CA, USA), in a 7500 Real-Time 
PCR system (Applied Biosystems, Foster City, CA, USA), according to the recommended 
protocol. ). A TaqMan® MGB probe contains a reporter dye linked to the 5’-end and a 
minor groove binder (MGB) at the 3’-end. Besides MGB, there is also a non-fluorescent 
quencher (NFQ) at the 3’-end of the probe. During PCR, the TaqMan® MGB probe 
anneals specifically to a complementary sequence between the forward and reverse 
primer sites (Figure 10 I). The DNA polymerase cleaves only probes that are hybridized to 
the target separating the reporter dye from the quencher dye and the separation results in 
increased fluorescence by the reporter (Figure 10 II). This fluorescence is read by Real-
Time PCR System and it is proportional to the amount of PCR product. 
Briefly, for each well was added 0.5μL of TaqMan Small RNA Assay (20x), 0.75μL 
of RT product, 5μL of TaqMan Universal PCR Master Mix II no UNG (2x), and 3.75μL of 
nuclease-free water. According to manufacturer’s instructions, protocol conditions were: 
Figure 9: Reverse transcription reaction. Adapted from MegaplexTM Pools For microRNA 
Expression  Analysis 
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50°C for 2 min, 95°C for 10min, followed by 40 cycles at 95°C for 15sec and 60°C for 
1min. Expression of five selected miRNAs were assessed, using taqMan® microRNA 
assays: hsa-miR-21 (RT00397), hsa-miR-141 (RT000463), hsa-miR155 (RT002623), has-
miR-183 (RT002269) and hsa-miR-200b (RT002251).  All samples were run in triplicate 
and two water blanks were added to each plate as negative controls. 
Results from the qRT-PCR were analyzed using the 7500 Software version 2.0.5 
(Applied Biosystems, Foster City, CA, USA). Levels of miRNAs expression were 
determined using the relative standard curve method, which provides more accurate 
quantitative results in comparison with the ΔΔCt method [131].  
In each sample, the mean quantity of each miRNA was normalized to the mean 
quantity for the endogenous controls RNU48 (RT001006) and RNU6B (RT001093), 
according to the following formula:  
 
 
 
 
 
 
 
F 
 mean)/2quantity  RNU6B +mean quantity  (RNU48
quantitymean miRNA 
 expressionmiRNA 
Figure 10: Quantitative reverse transcription-PCR reaction. TaqMan® technology 
chemistry. MGB – minor groove binder; NFQ – non- fluorescent quencher; R – reporter; P 
– DNA polymerase. Adapted from TaqMan® Small RNA Assays protocol.  
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5. Statistical analysis  
Differences in expression levels of the related miRNAs between the different 
histological subtypes were firstly analyzed using non-parametric Kruskal-Wallis test, 
followed by pairwise comparisons using non-parametric Mann-Whitney U-test. The 
relationship between miRNAs expression and clinico-patological variables (gender, 
pathological stage, Fuhrman grade) was evaluated using Mann-Whitney U-test. A 
Spearman Nonparametric Correlation Test was additionally carried out to ascertain 
correlation values between age and miRNAs expression levels. A Receiver Operator 
Characteristics (ROC) curve was created by plotting the true positive rate (sensitivity) 
against the false positive rate (1-specificity). In order to perform a panel of two 
microRNAs, we used logistic regression, and the areas under the curve (AUC) were 
calculated. Disease-specific survival curves (Kaplan-Meier with log-rank test) were 
computed for standard variables such as histological subtype, pathological stage, 
Fuhrman grade, age, gender and also miRNA expression levels. A Cox-Regression model 
comprising all significant variables and the Fuhrman grade (multivariate test) was 
computed to assess the relative contribution of each variable to the follow-up status. In 
statistical analyses, pathological stage and Fuhrman grade was recode into groups (pT1- 
pT2 versus pT3- pT4 and grade 1-2 versus 3-4, respectively).  
Statistical analysis was performed using SPSS for Windows, version 20.0 [SPSS, 
Chicago, IL, USA], and considered statistically significant when p < 0.05, and when 
comparing multiple groups p value was adjusted with the Bonferroni method, thus 
significance value was set at p < 0.017. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results
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Clinical Samples 
Relevant clinical and pathological features of the patients included in this study are 
summarized in Table 2. No significant differences in age or gender between RCTs 
patients and normal tissue donors were apparent.  
 
Table 2: Clinical and pathological features of patients included in this study, including the 
data for the two sets of samples (Fresh frozen tissues and ex-vivo biopsies) 
  Fresh frozen tissues 
Ex-vivo aspiration 
biopsies 
  Tumor Normal Tumor 
Number of patients, n  120 10 60 
Age, median (range) 62 (30-84) 65 (20-83) 60 (30-82) 
Gender, n (%)    
Male 71 (59.2) 7 (70.0) 35 (58.3) 
Female 49 (40.8) 3 (30.0) 25 (41.7) 
Histological subtype, n (%)  n.a.  
Clear cell RCC 30 (25.0)  15 (25.0) 
Papillary RCC 30 (25.0)  15 (25.0) 
Chromophobe RCC 30 (25.0)  15 (25.0) 
Oncocytoma 30 (25.0)  15 (25.0) 
Pathological stage, n (%)  n.a.  
pT1 46 (38.3)  25(41.7) 
pT2 19 (15.9)  8(13.3) 
pT3 24 (20.0)  12(20.0) 
pT4 1 (0.8)  - 
N.A. (oncocytoma) 30 (25.0)  15(25.0) 
Furhman grade, n (%)  n.a.  
1 3(2.5)  0 (0.0) 
2 27(22.5)  12 (20.0) 
3 44 (36.7)  20 (33.3) 
4 16 (13.3)  12 (20.0) 
n.a. 30 (25.0)  16 (26.7) 
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MicroRNA expression levels and 
clinicopathological correlates 
 
The relative expression levels of miR-21, miR-141, miR-155, miR-183 and miR-200b were 
determined in fresh frozen tissues of 120 RCTs and 10 normal renal tissue samples. No 
statistically significant associations were disclosed between miRs expression levels and 
any of the clinicopathological characteristics (age, gender, Fuhrman grade categories or 
pathological stage). RCTs showed significantly lower expression levels of miR-21, miR-
141, and miR-200b compared with normal tissues (p < 0.001 for all; Figure 11A and 
Supplementary Table 1). Moreover, expression levels of all target miRs differed 
significantly between benign and malignant RCTs. Oncocytomas displayed lower 
expression levels for all tested miRs except miR-183 (Figure 11B and Supplementary 
Table 2).  
 
Figure 11: Distribution of microRNAs expression levels in kidney tissues. A: normal vs. 
tumor tissues. B: benign vs. malignant tumor tissues. Statistically significant differences 
are represented with three asterisks (p<0.001), two asterisks (p <0.01) and one asterisk 
(p<0.02). 
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Expression levels of all miRs differed significantly among the four RCT subtypes (p < 
0.001 for all, Kruskall-Wallis test; Table 3). Pair-wise comparisons are shown in Table 4 
and graphically illustrated in Figure 12. 
Generally, oncocytomas displayed the lower miR expression levels, significantly differing 
from pRCC or ccRCC in four miRs (miR21, miR-155, miR-183 and miR-200b), and from 
chRCC in two miRs (miR141 and miR-200b). Interestingly, ccRCC and pRCC only 
differed for miR-155 expression levels whereas chRCC differed from ccRCC and pRCC 
for miR-21, miR-141 and miR-155 expression levels. In addition miR-183 expression 
levels were also different between chRCC and ccRCC Table 4. Thus, reduced expression 
of miR-200b surfaced as the most discriminative feature between oncocytomas and 
RCCs. 
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Figure 12: Distribution expression levels of miR-21, miR-141, miR-155, miR-183 and miR-
200b according with the histological subtype of RCTs. Statistically significant differences 
are represented with three asterisks (p<0.001), two asterisks (p< 0.003) and one asterisk 
(p<0.0125). 
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Table 3: Distribution of microRNAs expression levels among different histological subtypes in fresh-frozen tissues. 
 Oncocytoma chRCC pRCC ccRCC p-value, K-W 
miR-21 5.3 (0.02-60.9) 4.0 (0.8-560.2) 47.9 (0.6-689.3) 155.5 (3.5-1325.8) <0.001 
miR-141 7.9 (0.2-45.9) 83.5 (0.3-552.2) 76.8 (0.3-2063.3) 25.75.7 (0.3-301.2) <0.001 
miR-155 374.9 (1.1-233.7) 339.6 (14.5-5340.1) 1054 (17.1-4595.9) 3148.8 (23.74-13299) <0.001 
miR-183 5034.7 (87.1-23207.1) 1690.3 (18.8-8013.8) 1350.1 (7.7-13865) 512.5 (15.9-2360.7) <0.001 
miR-200b 40.3 (1.1-161) 367.9 (3.3-1244) 611.6 (4.8-7445.1) 249.1 (38.1-930.2) <0.001 
K-W, Kruskall-Wallis test; ccRCC, clear cell renal cell carcinoma; pRCC, papillary RCC; chRCC, chromophobe RCC 
 
 
Table 4: Comparison of microRNA´s expression among renal cell tumor subtypes in fresh-frozen tissues. 
  p-value*, M-W test 
  miR-21 miR-141 miR-155 miR183 miR-200b 
Oncotytoma vs. ccRCC <0.001 n.s. <0.001 <0.001 <0.001 
Oncocytoma vs pRCC <0.001 n.s. 0.012 <0.001 <0.001 
Oncotytoma vs. chRCC n.s. 0.001 n.s. n.s. 0.001 
pRCC vs. ccRCC n.s n.s. 0.003 n.s. n.s. 
ccRCC vs. chRCC  <0.001 0.002 <0.001 <0.001 n.s. 
pRCC vs. chRCC <0.001 <0.001 0.002 n.s. n.s. 
*Statistically significant when p<0.0125, Bonferroni’s correction; M-W, Mann-Whitney test; ccRCC, clear cell renal cell 
carcinoma; pRCC, papillary RCC; chRCC, chromophobe RCC; n.s., not significant. 
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Diagnostic performance of microRNAs 
expression levels in tissue samples 
The performance of the five target miRs was assessed in three different settings: 
identification of RCTs (vs. normal renal tissue), discrimination of malignant from benign 
tumors, and distinction of chRCC from oncocytoma. For these purpose, the cutoff value 
was the highest value obtained by the ROC curve analyses (sensitivity + (1-specificity)). 
Validity and information estimates for each marker and for the best combination of 
markers are displayed in Table 5. ROC curve analysis showed that a panel comprising 
expression of miR-141 and miR-200b allowed for the discrimination between RCT and 
normal renal tissue with 99.2% sensitivity and 100% specificity, corresponding to an AUC 
of 0.991. 
Table 5: Validity estimates for each tested miR and for the best combination of 
miRs in each diagnostic setting, in fresh-frozen tissues 
 (%) miR-21 miR-141 miR-155 miR-183 miR-200b miR-141/miR-200b 
  
  
RCT 
vs. 
NRT 
  
SE 76.7 81.7 – – 97.5 99.2 
SP 100 100 – – 100 100 
PPV 100 100 – – 100 100 
NPV 26 31 – – 77 90.9 
Accuracy 78 83 – – 98 99.2 
AUC 89.9 89.7 – – 98.7 99.1 
  
  
RCC 
vs. 
Onc 
   
SE 48.9 25.6 50.0 72.2 96.7 85.6 
SP 93.3 100 83.3 73.3 90.0 100 
PPV 95.7 100 90.0 89.0 96.7 100 
NPV 37.8 13.0 35.2 46.8 67.5 69.8 
Accuracy 60.0 33.0 58.3 72.5 95.0 89.2 
AUC 75.9 64.9 66.7 75.1 91.4 91.4 
  
  
chR
CC 
vs. 
Onc 
 
SE – 76.7 – – 83.3 90.0 
SP – 86.7 – – 90.0 100 
PPV – 85.2 – – 89.3 100 
NPV – 78.7 – – 84.4 90.9 
Accuracy – 81.6 – – 86.7 95.0 
AUC – 81.9  – 89.6 90.0 
Se: sensitivity; Sp: specificity; PPV: positive predictive value; NPV: negative predictive value; AUC, area 
under the curve; RCT, renal cell tumor; RCC, renal cell carcinoma; chRCC: chromophobe RCC: NRT: 
normal renal tissue; Onc: oncocytoma 
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Moreover, the same panel allowed for the differentiation between benign and malignant 
tumors with 85.6% sensitivity and 100% specificity, displaying an AUC of 0.912. 
Furthermore, expression levels of miR-141 and miR-200b also distinguished chRCC from 
oncocytoma with 90% sensitivity and 100% specificity, corresponding to an AUC of 0.90 
(Figure 13 A-B). 
 
Figure 13: Receiver operator characteristic (ROC) curves evaluating the performance of 
the gene panel (miR-141 and miR-200b): (A, C) as a biomarker for malignant renal tumors 
(B, D) as a biomarker of chRCC. A and B were performed in kidney tissue samples; C and 
D in ex vivo aspiration renal biopsies 
 
Survival analysis 
The median follow-up of this series of RCT patients was 65 months (range: 1-120 
months). A total of 12 patients (13.3%) have died from RCC during this period. Disease-
specific survival (DSS) analysis showed that tumor subtype ccRCC or pRCC and higher 
pathological tumor stage (pT3-T4) were significantly associated with worse outcome (p = 
0.011 and p < 0.001, respectively; Figure 14A-B).  
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Although age at diagnosis over 62 years was associated with worse DSS (p=0.035), 
gender and Fuhrman grade did not disclose any prognostic value within the available 
follow-up time. Concerning microRNAs expression levels, miR-200b and miR-183 did not 
display any prognostic value. However, high expression levels of miR-21 and miR-155 
and low expression levels of miR-141 were associated with worse DSS (p = 0.006, p = 
0.037 and p = 0.024, respectively; Figure 14C-E). However, in multivariate analysis only 
pathological stage independently predicted prognosis, whereas miR expression levels did 
not retain independent prognostic value (Supplementary Table 3).  
 
Figure 14: Disease-specific survival according to pathological and molecular parameters. 
(A) histopathological classification; (B) pathological stage; (C-E) miR expression levels. 
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Validation of the microRNA panel in ex-vivo 
aspiration biopsies 
The two best performing miRNA in tissue samples, miR-141 and miR-200b, were then 
selected for analysis in ex vivo aspiration biopsies. This set comprised 60 ex vivo fine-
needle aspiration biopsies. Relevant clinical and histopathological data are summarized in 
Table 2 and the relative expression levels for each miR are depicted in Supplementary 
Table 4. 
The expression of these two microRNAs in ex-vivo aspiration biopsies follows the same 
trend observed in fresh frozen tissues. Not only when we compared the expression of 
microRNAs between malignant and benign tumors (Figure 15) , but also when comparing 
the different histological subtypes (Figure 16).  
 
Figure 15: Distribution of miR-141 and miR-200b expression levels in benign and 
malignant tumors of ex vivo kidney aspiration biopsies. Statistically significant differences 
are represented with one asterisks (p<0.001). 
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Figure 16: Distribution of miR-141 and miR-200b expression levels according with the 
histological subtype of RCTs in ex vivo kidney aspiration biopsies. Statistically significant 
differences are represented with one asterisk (p<0.005) and two asterisks (p<0.001). 
 
Remarkably, expression levels of this panel of microRNAs was able not only distinguish 
benign from malignant RCT with 73.3% sensitivity and a 100% specificity (AUC of 90.4%), 
but also oncocytoma from chRCC with 100% sensitivity and 100% specificity (AUC of 
100%) (Figure 13C-D; Table 6). 
Table 6: Validity estimates for each tested miR and for the best combination of miRs in 
each diagnostic setting, in ex vivo aspiration biopsies 
  (%) miR-141 miR-200b miR-141/miR-200b 
  SE 35.5 73.3 73.3 
  SP 93.3 93.3 100 
  PPV 94.1 97.1 100 
RCC vs. oncocytoma  NPV 34.5 53.8 55.0 
  Accuracy 50.0 78.3 80.0 
  AUC 57.5 88.4 90.4 
  SE 73.3 100 100 
  SP 93.3 100 100 
  PPV 91.6 100 100 
chRCC vs. oncocytoma  NPV 77.7 100 100 
  Accuracy 83.3 100 100 
  AUC 84.4 100 100 
Se: sensitivity; Sp: specificity; PPV: positive predictive value; NPV: negative predictive value; AUC, area under the curve; 
RCC, renal cell carcinoma; chRCC: chromophobe RCC 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion
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In this study we aimed to define a small set of miRs that might allow for accurate 
identification of RCTs, as well as for discrimination between oncocytoma and RCCs, 
especially chRCC. The definition of such panel would be of clinical relevance as 
diagnostic workup of suspicious renal masses incidentally found by abdominal 
ultrasonography is increasingly more frequent and demanding. Indeed, each RCT subtype 
displays quite dissimilar clinical behavior, ranging from totally benign to overtly malignant 
and successful pre-therapeutic cytological or histological assessment is limited [45,46]. 
Only a few studies addressed the use of miRNAs expression as biomarkers for RCTs 
detection, and these have been mainly restricted to the ccRCC subtype, or have analyzed 
only a very limited number of samples [49,115,116,120,126,132]. After an extensive 
review of published literature, we selected five miRNAs (miR-21, miR-141, miR-155, miR-
183 and miR-200b) with putative diagnostic and/or prognostic value [129,130], and tested 
them in a relatively large set of tissue samples that comprised the major histological 
subtypes. To ascertain their clinical and pathological relevance, a validation study was 
subsequently performed in a set of ex vivo fine-needle aspiration biopsies. 
Of the five miRs tested, three (miR-21, miR-141 and miR-200b) were significantly 
downregulated in RCTs compared to normal renal tissue, whereas the remainder did not 
disclose statistically significant differences. In three previous reports, miR-21 was found to 
be upregulated in RCT [114,115,127], which apparently contradicts our results. However, 
in those studies normal renal tissue was obtained from nephrectomy specimens harboring 
RCT, which did not occur in our study as normal renal tissue was collected from kidneys 
harboring urothelial tumors of the renal pelvis. This is an important issue as we have 
previously showed that morphologically normal renal tissue from kidneys harboring RCT 
display epigenetic alterations in line with the respective tumors [133]. Remarkably, 
variations in miR-21 expression among RCT subtypes observed in our study matches that 
reported by Faragalla and co-workers [114], with ccRCC depicting the highest median 
levels, followed by pRCC, chRCC and oncocytoma. Indeed, only miR-21 expression 
levels of “normal renal tissue” are notably different between our results and their study 
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[114]. These findings prompt the need for an adequate definition of “normal tissue” as the 
interpretation of results in tumors might be considerably biased. 
Concerning miR-141, our results corroborate those of two previous reports 
[124,125], in which the highest expression levels of miR-141 were observed in chRCC 
and these were significantly different from all the other RCT subtypes. Thus, high miR-141 
expression levels seem to be a hallmark of chRCC and might constitute a valuable 
biomarker for discrimination from oncocytoma. Strikingly, a miR profiling of ccRCC, also 
identified miR-141 (and 200b) as being downregulated in ccRCC, although with 
concurrent upregulation of miR-155 [120]. These results are in line with ours as we found 
that the highest miR-155 expression levels in ccRCC and pRCC, significantly differing 
from those of oncocytoma and chRCC. Our findings concerning miR-200b mirror those of 
Youssef et al. [49], which observed increased expression in chRCC compared to 
oncocytoma, although in a smaller dataset. Interestingly, in our larger dataset we were 
able to demonstrate that miR-200b expression levels were significantly lower in 
oncocytomas, compared to all RCC subtypes. Overall, the comparisons of miRs 
expression levels among RCT subtypes also denote the common origin (segment of the 
nephron) of ccRCC and pRCC, on one hand, and of chRCC and oncocytoma, on the 
other hand, emphasizing the importance of searching for discriminative biomarkers, which 
might enable accurate identification of each RCT subtype. 
Once the main purpose of this study was the identification of small panel of 
biomarkers based on specific miRs expression levels, we chose the two miRs that jointly 
might allow for accurate discrimination between normal kidney and RCTs as well as that 
of oncocytomas from RCC, in general, and chRCC, in particular. A panel comprising miR-
141 and miR-200b demonstrated the best performance in frozen-tissue samples, 
displaying AUC values ranging from 90.0 to 99.1. Although these results are interesting 
per se, its clinical usefulness depends on the possibility of using it in diagnostic samples. 
For that purpose, we further validated this biomarker panel in a set of fine-needle 
aspiration biopsies performed ex vivo. Although this procedure is not completely 
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equivalent to an imaging-guided diagnostic fine-needle aspiration biopsy performed in a 
patient (which may yield lower amounts of tumor cells), it is, nonetheless, the best 
approximation without jeopardizing patients’ diagnosis. On the other hand, because the 
nephrectomy specimen is already available, its histopathological characterization is 
guaranteed whereas diagnostic biopsies may not be followed by surgical excision, thus 
precluding accurate tumor classification for comparison purposes. Remarkably, the 
biomarker panel performance in ex vivo biopsies was comparable to that of fresh-frozen 
tissues. To the best of our knowledge, this is the first attempt to demonstrate the feasibility 
of using miRs as tumor biomarkers in renal tumor biopsies, and may thus constitute a 
significant step forward in the development of epigenetic-based biomarkers for 
management of RCC suspects. 
The clinical significance of our findings could be extended if miRs expression 
levels might convey prognostic information. Thus, we performed disease-specific survival 
analysis using expression levels determined in fresh-frozen tissue samples. As expected, 
tumor subtype and pathological stage were of prognostic value in univariate analysis, 
although only the later showed independent prognostic value in multivariate analysis. 
Remarkably, miR-21, miR-141 and miR-155 expression levels also displayed prognostic 
significance in RCC, although only in univariate analysis. A possible explanation for these 
findings may lie in the association between specific miRs expression levels and tumor 
subtypes. Indeed, whereas for miR-21 and miR-155 the association with poorer DSS was 
observed for higher (> median) expression levels, the opposite was verified for miR-141. 
Interestingly, higher miR-21 and miR-155 and lower miR-141 expression levels were 
associated with pRCC and ccRCC subtypes, which displayed the worse prognosis, 
compared to chRCC. The fact that tumor subtype did not surfaced as independent 
prognostic parameter for DSS in multivariate analysis is most likely due to the association 
between tumor subtype and pathological stage, as pT3-4 tumors were mostly of pRCC or 
ccRCC subtype. Our findings concerning miR-21 and miR-141 are corroborated by 
previous reports, although with generally smaller patient cohorts [114,120,127]. In 
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addition, the prognostic value of miR-155 expression levels has been reported for breast 
cancer [134] and non-small cell lung cancer [135,136], whereas miR-21 and miR-141 
expression seem to be of prognostic significance in non-small cell lung cancer [135,136] 
and colon cancer [137], respectively. 
The aforementioned association of specific miRs altered expression and RCT 
subtype might also provide clues concerning the cause of miRs dysregulation. It is widely 
acknowledged that RCT subtypes display characteristic chromosomal aberrations, 
including whole or partial deletions and/or duplications [16]. Strikingly, some of those 
alterations might explain the altered pattern of miRs expression. For instance, miR-200b is 
mapped at 1p36.33 and loss of 1p or of the whole chromosome 1 is frequently observed 
in oncocytoma and chRCC. On the other hand, miR-21 and miR-155 are mapped at 
17q23.1 and 21q21.2-21.3, which are frequently lost chromosomal regions in chRCC. 
Conversely, pRCC, which commonly show gain of chromosome 17, are among the RCT 
subtypes with higher miR-21 expression levels. However, other variations in miRs 
expression might not be explained by chromosomal-level alterations and the respective 
cause(s) remain to be investigated. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusion
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Herein, we demonstrate that expression levels of a panel of two miRNAs (miR-
141/miR200b) allows for accurate distinction of normal kidney from RCT tissue samples, 
as well as for accurate discrimination among RCT subtypes, including the separation of 
benign from malignant RCT. Furthermore, the selected miR panel is able to convey 
prognostic information, although not independent of tumor subtype or pathological stage. 
Importantly, the same panel displays an impressive performance for accurate detection of 
RCC in clinical samples obtained from ex vivo fine-needle aspiration biopsies, 
demonstrating the feasibility of this approach in routine diagnostic practice.  
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Supplementary Table 1 : Expression levels of microRNAs in fresh-
frozen tissues from normal kidney and renal cell tumors. 
M-W, Mann-Whitney test; med, median value; min, minimum value;max, 
maximum value 
 
 
 
Supplementary Table 2: Expression levels of microRNAs in fresh-frozen 
tissues from benign (oncocytoma) and malignant (clear cell, papillary and 
chromophobe carcinomas) renal cell tumors 
 Benign tumors Malignant tumors P-Value (M-W) 
miR-21 5.3 (0.02-60.9) 9.7 (0.6-1325.8) <0.001 
miR-141 7.9 (0.23-45.9) 62.0 (0.3-2063.3) 0.015 
miR-155 374.6 (1.10-233.7) 1538.6 (7.1-13299) 0.006 
miR-183 5034.7 (87.0-23207.1) 1184.3 (7.2-1385) <0.001 
miR-200b 40.3 (1.09-161) 230.0 (3.3-7445.1) <0.001 
M-W, Mann-Whitney test  
 Normal Tumor P-Value (M-W) 
miR-21 (med, min-max) 357.0 (97.9-1477.9) 106.4 (0.02-1325.1) <0.001 
miR-141 (med, min-max) 93.4 (47.9-134.9) 48.5 (0.2-2026.3) <0.001 
miR-155 (med, min-max) 688.5 (17.2-13298.9) 1229.5 (1.1-13299.0) 0.231 
miR-183 (med, min-max) 873.7 (361.5-2360.9) 1897.8 (7.7-23207.1) 0.993 
miR-200b (med, min-max) 1820.8 (1317.2-2336.9) 319.3 (1.1-7445) <0.001 
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Supplementary Table 3: Cox regression models assessing the potential of 
clinical variables and miR´s in the prediction of disease-specific survival for 90 
patients with renal cell carcinoma.  
  HR (95% CI for HR) 
 Histological subtype  
 ccRCC 0.55 (0.03-8.15) 
 pRCC 4.37 (0.29-65.00) 
miR-21 High pathological Stage 9.69 (2.43-38.71) 
 Age>med 4.64 (0.961-22.35) 
 miR-21>med 4.84 (0.641-36.52) 
 Histological subtype  
 ccRCC 0.80 (0.07-9.24) 
 pRCC 7.638 (0.70-82.63) 
miR-141 High pathological Stage 11.25 (2.90-43.71) 
 Age>med 4.07 (0.86-19.42) 
 miR-141≤med 3.62 (0.62-21.05) 
 Histological subtype  
 ccRCC 1.22 (0.011-13.19) 
 pRCC 13.32 (1.36-130.99) 
miR-155 High pathological Stage 11.90 (2.68-52.86) 
 Age>med 4.83 (1.00-23.22) 
 miR-155>med 1.50 (0.267-8.482) 
med, median value, ccRCC, clear cell renal cell carcinoma; pRCC, papillary RCC;  
 
 
Supplementary Table 4:  Distribution of microRNAs expression levels among 
the different histological subtypes in kidney in ex-vivo biopsies. 
ccRCC, clear cell renal cell carcinoma; pRCC, papillary RCC; chrRCC, chromophobe RCC; K-W, 
Kruskall-Wallis test 
 
 
 
 
 miR-141 P-Value (K-W) miR-200b P-Value (K-W) 
Tumor subtype  <0.001  <0.001 
Oncocytoma 3.0 (0.6-427.3)  49.27 (3-129.8)  
chRCC 113.5 (1.5-252.3)  49.3 (3-129.8)  
pRCC 20.2 (1.1-140.2)  333.8 (50.8-
863.8) 
 
ccRCC 14.3 (72.4-0.1)  138.16 (4.2-573)  
